XXXX in combination with sargramostim for treatment of recurrent @entity2946 .

@entity1 @entity137 @entity882 @entity548 @entity786 @entity1398 @entity358 @entity56 @entity2946
Thirteen @entity1 with recurrent @entity2946 were treated with @entity786 in association with Sargramostim. @entity786 was given at doses ranging between 1.0-2.5 g/m2 daily for two doses. Sargramostim was given at a fixed dose of 250 micrograms/m2 subcutaneously twice a day beginning 24 hours after the second @entity786 dose and continuing through the leukocyte nadir until the ANC was more than 1,000 cells/microliters for two consecutive days. A total of 33 courses were given with @entity137 consisting of grade 4 @entity1398 in all courses and grade 3-4 @entity882 in 10 of 13 @entity1 . There were no deaths related to @entity548 . Four @entity1 were taken off study because of prolonged myelosuppression. Three of these @entity1 were at the 2.5 g/m2 level, and of these three, two developed @entity358 (grades 2 and 4, respectively). One @entity1 developed an @entity56 following the first injection of Sargramostim and was also taken off study. Of 10 evaluable @entity1 , there were 9 PR and 1 SD. We conclude that @entity786 at a dose of 2.0 g/m2/day x 2 days q 4 weeks in association with Sargramostim demonstrates marked activity with acceptable @entity137 in @entity1 with recurrent @entity2946 .
